Eli Lilly (NYSE: LLY) has expanded its collaboration with Sweden-based Camurus (Nasdaq: CAMX) to include amylin receptor agonists, exercising a pre-negotiated option embedded in the original June 2025 agreement and triggering a USD 5 million payment to the Swedish drug delivery company. The move extends Lilly's exclusive, global rights to Camurus' FluidCrystal injectable depot platform across a third compound class, bringing the collaboration to up to four proprietary Lilly compounds spanning dual GLP-1/GIP agonists, triple GLP-1/GIP/glucagon agonists, and now amylin receptor agonists. The full agreement carries a headline value of up to USD 870 million, comprising up to USD 290 million in upfront, development, and regulatory milestones and up to USD 580 million in sales-based payments, plus tiered mid-single-digit royalties.
The option exercise is a follow-on event to the original collaboration initiated in June 2025, under which Lilly secured exclusive worldwide rights to apply FluidCrystal technology to its cardiometabolic peptide pipeline. The amylin compound is subject to the same milestone and royalty terms as the other compounds already covered by the deal. Financial terms of the original agreement — including the specific upfront payment — were not individually disclosed at signing and remain undisclosed.
Deal context
FluidCrystal is a lipid-based, in situ-forming injectable depot system developed by Camurus. Administered as a low-viscosity liquid via a prefilled syringe or autoinjector pen, the formulation undergoes spontaneous phase transition upon contact with subcutaneous tissue fluid, self-assembling into a liquid crystalline gel that encapsulates the active pharmaceutical ingredient and releases it gradually as the matrix biodegrades. The lipid excipients — including glycerol dioleate and phosphatidylcholine — are endogenous compounds metabolized via normal lipid pathways, distinguishing the platform from synthetic polymer-based competitors such as PLGA microsphere systems or solvent-exchange depots like Atrigel.
The platform's commercial and regulatory credentials are established. Buvidal, Camurus' long-acting buprenorphine depot for opioid use disorder, is approved across Europe, Australia, and several other markets; its US equivalent, Brixadi, is licensed to Braeburn Pharmaceuticals. In the endocrine space, Camurus' CAM2029 — an octreotide depot for acromegaly — has navigated a regulatory path that included FDA acceptance of an NDA resubmission in January 2026 with a PDUFA date of June 10, 2026, following positive Phase III results from the ACROINNOVA 2 study reported in mid-2024. CAM2029 data demonstrated approximately five-fold higher bioavailability versus intramuscular Sandostatin LAR, a benchmark that has been central to Camurus' platform differentiation narrative.